Software Defined Radio for NB-IoT

The next generation of mobile radio systems is expected to providing wireless connectivity for a wide range of new applications and services involving not only people but also machines and objects. Within few years, billions of low-cost and low-complexity devices and sensors will be connected to the Internet, forming a converged ecosystem called Internet of Things (IoT). As a result, in 2016, 3GPP standardizes NB-IoT, the new narrowband radio technology developed for the IoT market. Massive connectivity, reduced UE complexity, coverage extension and deployment flexibility are the targets for this new radio interface, which also ensures harmonious coexistence with current GSM, GPRS and LTE systems. In parallel, the rise of open-source software combined with Software Defined Radio (SDR) solutions has completely changed radio systems engineering in the late years. This thesis focuses on developing the NB-IoT’s protocol stack on the EURECOM’s open-source software platform OpenAirInterface (OAI). First part of this work aims to implement NB-IoT’s Radio Resource Control functionalities on OAI. After an introduction to the platform architecture, a new RRC layer code structure and related interfaces are defined, along with a new approach for Signalling Radio Bearers management. A deep analysis on System Information scheduling is conducted and a subframe-based transmission scheme is then proposed. The last part of this thesis addresses the implementation of a multi-vendor platform interface based on Small Cell Forum’s Functional Application Platform Interface (FAPI) standard. A configurable and dynamically loadable Interface Module (IF-Module) is designed between OAI’s MAC and PHY layers. Primitives and related code structures are presented as well as corresponding Data and Configuration’s procedures. Finally, the convergence of both NB-IoT and FAPI requirements lead to re-design PHY layer mechanisms for which a downlink transmission scheme is proposed

Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab

Objective: Ipilimumab is a human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4, that has been shown to significantly improve survival in patients with metastatic melanoma. Blocking cytotoxic T-lymphocyte antigen-4 elicits T cell activation, proliferation and anti-tumor response, but can also trigger immune-related adverse events. Among immune-related endocrinopathies, hypophysitis represents the most frequent, with an incidence up to 17% in patients treated with ipilimumab. Design and methods: We report nine cases of ipilimumab-induced hypophysitis in a cohort of 273 patients treated with ipilimumab between 2006 and 2015, as part of clinical trials or after its marketing. Thyroid function tests were scheduled at screening and during follow up (every 21 days) in all patients. Cortisol, adrenocorticotropic hormone, follicle-stimulating hormone, luteinizing hormone, and estradiol (for females) or testosterone (for males), prolactin, growth hormone, insulin-like growth factor 1 were measured only in case of clinical suspicion. Results: The incidence of hypophysitis was 3.3%. The most frequent pituitary failure was adrenocorticotropic hormone and thyroid stimulating hormone secretion with a complete recovery of thyroid stimulating hormone, but not of adrenocorticotropic hormone during follow up. All patients had negative pituitary antibodies. The main symptoms at diagnosis were fatigue and headache. Conclusion: Clinicians should be aware about the risk of hypophysitis during treatment with immune check-point inhibitors and the necessity of investigating pituitary function during therapy. Pituitary magnetic resonance imaging does not seem pivotal for a definite diagnosis if not performed at the onset of disease

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

Background: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in "real world" chronic hepatitis C patients in Italy. Methods: Independent observational multicentre study including consecutive patients receiving Peg-interferon/ribavirin in the 18 months before (retrospective phase) and after (prospective phase) the start of the study. Results: 4176 patients were eligible. The final study population consisted of 2051 patients in the retrospective and 2073 in the prospective phase.Sustained virological response was achieved by 1036 patients (50.5%) during the retrospective phase: 325 were genotypes 1/4 (34.1%) and 684 were genotypes 2/3 (67.2%) and by 800 patients (38.6%) during the prospective phase: 300 were genotypes 1/4 (28.4%) and 473 were genotypes 2/3 (51.5%).During multivariate analysis genotypes 2/3 were significantly associated with higher sustained virological response rates; cirrhosis and γ-glutamil-transpeptidase >2 times the normal limit were associated with poorer response. Conclusions: The response to Peg-interferon/ribavirin therapy in "real world" clinical practice is distinctly lower than in registration trials. The difference in response rates was more pronounced among easy-to-treat than among difficult-to-treat hepatitis C virus genotypes. © 2014 Editrice Gastroenterologica Italiana S.r.l